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Abstract:
Despite recent advances in DNA chip technology current microarray gene expres-
sion studies are still affected by high noise levels, small sample sizes and large num-
bers of uninformative genes. Combining microarray data with cellular pathway data by
using new integrative analysis methods could help to alleviate some of these problems
and provide new biological insights.
We present a method for learning simple decision rules for class prediction from
pairwise comparisons of cellular pathways in terms of gene set expression levels rep-
resenting the up- and down- regulation of pathway members. The procedure generates
compact and comprehensible sets of rules, describing changes in the relative ranks of
gene expression levels in pairs of pathways across different biological conditions. Re-
sults for two large-scale microarray studies, containing samples from prostate cancer
and B-cell lymphoma patients, show that the method provides robust and accurate rule
sets and new insights on differentially regulated pathway pairs. However, the main
benefit of these predictive models in comparison to other classification methods like
support vector machines lies not in the attained accuracy levels but in the ease of inter-
pretation and the insights they provide on the relative regulation of cellular pathways
in the biological conditions under consideration.
1 Introduction
Classification of microarray gene expression samples often suffers from several limitations
resulting from the high dimensionality of the data, a typically small number of available
samples, and from various sources of technical and biological noise. In recent years,
several methods have extended or replaced classical machine learning methods to provide
more compact, robust and easily interpretable classification models. These approaches
reduce the prediction model complexity and increase its robustness by using regularization
and shrinkage techniques [AMD+05, GHT07], by generating more human-interpretable
machine learning models, which are based on simple decision rules [A+06, BK08], or
by using more robust data representations and model formulations, e.g. computing rank
scores [WEB05] or only considering relative expression values by comparing pairs of
genes [G+04a, TNX+05].
In this paper, we address the problem of low model robustness due to noise by combining
ideas from the techniques mentioned above with an approach to analyse the data at the
level of pathways instead of at the single-gene level. Briefly, we map the genes in a
microarray study onto cellular pathways and processes from public databases and learn
simple decision rules for sample classification by comparing gene expression levels in
pairs of pathways. Rules describing single pathway-pairs are then weighted and combined
into a unified classification model by applying a boosting algorithm. The approach can
be understood as a methodological extension of the “top-scoring pairs” (TSP) algorithm
[G+04a, TNX+05], which identifies discriminative pairs of genes in microarray data, and
has therefore been named “top-scoring pathway pairs” (TSPP) algorithm. Moreover, we
draw inspiration from other pathway-based microarray analysis approaches, which use
summarized expression values for genes in cellular pathways and processes for enrichment
analysis (e.g. the methods GSEA [S+05], MaxMean [ET07] and the global test [G+04b])
or as features for sample classification [G+05].
In contrast to previous methods comparing single gene expression values or summarized
expression values for single pathways against fitted threshold values, TSPP provides in-
creased robustness by at the same time combining expression levels of multiple genes
into “pathway expression fingerprints” and making pairwise, relative comparisons between
pathways. In summary, the TSPP approach is not designed to compete with existing mi-
croarray sample classification and data mining methods, but to complement them with the
following added benefits:
• New biological insights can be gained from easily interpretable decision rules on the
relative up- and down-regulation of cellular pathways.
• The prediction models are applicable to data from other microarray platforms with-
out requiring that all platforms contain the same genetic probes and that cross-study
normalization is applied (the integration takes place at the level of pathways, and
the gene expression values are replaced by rank scores).
• By summarizing the expression values of multiple genes belonging to the same path-
way, the dimensionality of the data is reduced (from about 50.000 genes to a few
hundred pathways) and the summarized “pathway expression fingerprints” have a
higher robustness than single gene expression vectors (however, at the expense of
losing detail; therefore single-gene based methods should be applied additionally).
2 Methods
The TSPP algorithm identifies, scores and combines decision rules based on pathway-pairs
according to the following five-step procedure:
1. Rank score transformation:
A gene expression matrixX with dimension n×p (n: number of samples, p: number
of genes) and class labels y for the samples is read as input and transformed into a
“rank matrix” R by sorting the expression values for each gene across the n samples
and replacing them with their position index in the sorted vector (ties are handled
by replacing equal values by the mean of the corresponding position indices).
2. Pathway mapping:
Gene sets representing cellular pathways and processes are extracted from a public
database (e.g. KEGG, Gene Ontology, BioCarta or Reactome). Pathway assign-
ments are computed for the p genes in the microarray input data by testing whether
they occur in these gene sets. For genes which cannot be assigned to a pathway the
corresponding rows are removed from matrix R.
3. Scoring of pathway pairs:
To score a pair of pathways as being useful for discriminating between two sample
class labels 1 and 2, e.g. “tumour (1) vs. normal (2)” or “drug treatment (1) vs.
no treatment (2)”), the pathway-submatrices R1 and R2, corresponding to these two
samples classes, are extracted from matrix R based on the mappings from step 2.
The matrices R1 and R2 are then reduced to vectors r1 and r2 by replacing each
column of expression level ranks by its median value. For a two-class problem, the
score for a pathway-pair is then obtained by comparing the median ranks in pathway
1 to those in pathway 2 and computing the maximum of two relative frequencies:
The relative frequency of samples which are up-regulated for class 1 and down-
regulated for class 2, and vice versa, the relative frequency of cases which are down-
regulated for class 1 and up-regulated for class 2 (i.e. there are two possibilities for
the relation of sample ranks in two pathways to differ across the sample classes).
Given the sets of column indices for two sample classes S1 and S2, the final score
can thus be computed as follows:
partial score1 =
∑
i∈S1
I(r1i >= r2i) +
∑
i∈S2
I(r1i < r2i) (1)
partial score2 =
∑
i∈S1
I(r1i < r2i) +
∑
i∈S2
I(r1i >= r2i) (2)
score =
max(partial score1, partial score2)
|S1|+ |S2| (3)
where I is the indicator function. For a multi-class problem, a similar score can
be obtained by computing the mean of the scores obtained for all pairs of sample
classes.
4. Identification of top-scoring pairs:
By default top-scoring pathway pairs (TSPPs) are identified by performing an ex-
haustive search across all pairs of pathways. This should be feasible in most prac-
tical applications, because the number of pathways is typically much smaller than
the number of genes, and the scoring method is kept simple. Moreover, the method
does not assume that all genes in a pathway are either up- or down-regulated, but
searches for pairs of pathways for which many genes occurring in the first pathway
change their relation of expression level ranks across the sample classes to genes
in the second pathway. Nevertheless, it might be beneficial to investigate whether
alterations in the pathway definitions can provide improved results. Therefore, the
user can alternatively let the algorithm introduce “mutations” into the pathway gene
sets, by randomly adding or deleting genes up to a small user-defined maximum
number of mutations, and replacing the exhaustive search by a previously published
evolutionary search algorithm [JUA05]. Only one modification is applied to this
algorithm: A genome contains two bit-vectors representing two pathways and mu-
tations are only applied to one of these bit-vectors, selected randomly. The scoring
function in the evolutionary algorithm is the same as for the exhaustive search.
5. Classification model generation:
Each TSPP provides a simple decision rule for classifying microarray samples de-
pending on the relative median expression value ranks of their genes in a pair of
pathways. To combine multiple TSPPs into a unified classification model, we use
the TSPP decision rules as “base classifiers” in the Adaboost.M1 algorithm [FS96],
adding one decision rule at a time to the boosting model based on the order of the
TSPP-scores computed in step 3. This boosting scheme assigns weights to each
decision rule in the combined ensemble model, accounting for a rule’s prediction
accuracy and capacity to correctly classify samples that were misclassified by deci-
sion rules added in previous iterations of the algorithm. Previous experiments with
boosting and ensemble techniques applied to microarray data [GGK09, HPG+] have
shown that improvements can be obtained both in terms of robustness and accuracy.
Figure 1: An overview of the workflow in the TSPP algorithm (example data is derived from a
human prostate cancer microarray dataset [S+02b])
3 Results
The TSPP algorithm was applied to the gene expression matrices from two public microar-
ray studies covering different types of cancer: B-cell lymphoma [S+02a] (7129 genes and
77 samples) and prostate cancer [S+02b] (12600 genes and 102 samples). Both datasets
contain samples from two biological classes: In the B-cell lymphoma dataset 58 sam-
ples were obtained from patients suffering from diffuse large B-cell lymphoma (class D),
while the remaining samples derive from a related follicular B-cell lymphoma (class F).
The prostate cancer expression measurements were obtained from 50 healthy control tis-
sues (class C) and 52 tumour tissues (class T) (for details on the normalization and pre-
processing of the datasets, see the Data Sets section).
To evaluate the predictive accuracy for TSPP-models generated for these datasets, we ap-
plied an external leave-one-out cross-validation (LOOCV) procedure using different num-
bers of top-scoring pairs k (for k = 1, 3, 5, 10 and 15) and including all modelling steps
in the cross-validation procedure. The parameter k can be regarded as a bias/variance
trade-off, enabling the user to control the complexity of the generated classifiers. The
cross-validation results, computed both for mappings of genes to KEGG pathways and to
Gene Ontology (GO) terms, include the average accuracy, sensitivity and specificity for
each LOOCV run and are shown in Tables 1 and 2.
Table 1: Leave-one-out cross-validation results (TSPP on KEGG database)
Dataset No. of top- Sensitivity Specificity Avg.
scoring pairs (%) (%) Accuracy (%)
1 83.7 71.7 77.5
3 87.8 73.6 80.4
Prostate cancer 5 85.7 77.4 81.4
10 77.6 73.6 75.5
15 79.6 64.2 71.6
1 64.9 85.0 70.1
3 68.4 90.0 74.0
Lymphoma 5 78.9 90.0 81.8
10 77.2 90.0 80.5
15 75.4 90.0 79.2
In summary, average classification accuracies above 70% were obtained in all cases, and
for both datasets the best accuracies (prostate cancer: 81.4%, DLBCL: 81.8%) were
achieved when using 5 top-scoring pairs, suggesting that k = 5 represents a reasonable
bias/variance trade-off. The sensitivity and specificity scores were in a roughly similar
percentage range.
Apart from using the decision rules for class prediction, their simplicity also makes them
suitable for direct human interpretation. The ten top-scoring pathway pairs for each dataset
are shown in Tables 4 and 5. Interestingly, the top-ranked rule for the prostate cancer
dataset contains the KEGG-pathways “Prostate cancer” and “Insulin signaling”, which
are both known to be de-regulated in the disease [SK03, H+01]. However, the results
Table 2: Leave-one-out cross-validation results (TSPP on GO database)
Dataset No. of top- Sensitivity Specificity Avg.
scoring pairs (%) (%) Accuracy (%)
1 83.7 67.9 75.5
3 89.8 67.9 78.4
Prostate cancer 5 89.8 69.8 79.4
10 91.8 66.0 78.4
15 85.7 67.9 76.5
1 68.4 80.0 71.4
3 57.9 90.0 66.2
Lymphoma 5 71.9 90.0 76.6
10 52.6 90.0 62.3
15 71.9 85.0 75.3
Table 3: Leave-one-out cross-validation results (Gene-based: eBayes & SVM)
Dataset No. of features (genes) Sensitivity Specificity Avg. Accuracy (%)
2 88.0 84.6 86.3
6 96.0 88.5 92.2
Prostate cancer 10 96.0 86.5 91.2
20 90.0 88.5 89.2
30 90.0 90.4 90.2
2 91.4 68.4 85.7
6 93.1 78.9 89.6
Lymphoma 10 94.8 94.7 94.8
20 96.6 84.2 93.5
30 98.3 100.0 98.7
also point to relative de-regulations in other pathways with less obvious associations to
the cancer disease, e.g. “Pyrimidine metabolism” and “Glycerolipid metabolism”, with a
score close to the best-ranked pair. Similarly, for the B-cell dataset the top-ranked path-
way pairs contain pathways known to be associated with B-cell neoplasia, e.g. the “Wnt
signaling pathway” [QERR03, LB03], whereas for other pathways no direct and specific
associations with the disease are known. In spite of the class-imbalance in this dataset,
the prediction models did not display a preference to assign samples to the majority class;
however, similar to other statistical methods for microarray data analysis, problems with
robustness can occur when the sample size per condition is very small. Thus, when plan-
ning a microarray study, the experimenter might first want to study the literature on sample
size estimation [LHC10], microarray study design [Chu02] and sampling techniques to al-
leviate these problems [VHKNW09].
It is also important to note that in a top-scoring pathway pair (TSPP) not necessarily both
pathways are differentially regulated across the sample classes, but one pathway might
have a constant expression, while the other pathway is highly de-regulated in one of the
sample classes. The main benefit of comparing pairs of pathways lies in the possibility
to avoid comparing single pathways against fitted thresholds, which would more likely
be affected by experimental bias and thus provide prediction models with higher gener-
alization error. However, if a user’s main goal is not to obtain a prediction model from
the TSPP-algorithm, but to identify pathway associations, then TSPPs in which one of the
pathways is not differentially regulated across the sample classes can easily be identified
and filtered out by computing the variance for the corresponding gene expression vectors
and removing TSPPs containing a pathway with low variance.
When using the evolutionary search methodology and allowing the algorithm to intro-
duce small numbers of random gene deletions and insertions into the pathways (up to five
genes), in spite of the higher flexibility of this method, in all experiments the prediction
accuracies are either similar or lower than those obtained for the original pathways using
an exhaustive search (data not shown). The weaker performance might result from an en-
trapment in local minima due to the expansion of the search space, but could also suggest
that the original pathways and processes are already well defined and therefore hard to
optimize based on an evolutionary search procedure.
Overall, the results from the cross-validation analysis and the lists of top-scoring pathways
show that the method can generate compact predictive models with both high interpretabil-
ity and high accuracy in comparison with a random model predictor (when measuring this
using the “proportional chance criterion” by Huberty [Hub94], we obtain p-values < 0.01
in all cases). To put these results into relation with existing machine learning methods
based on single genes as predictors, we applied a C-SVM from the e1071 R software
package [DHL+05], a wrapper for the well-known LibSVM library [CL01], with different
kernel functions, including the radial basis function and polynomial kernels with a degree
up to 3 (the results for the best kernel, a linear SVM, are reported in Table 3). The gene-
based SVM-models achieve higher average accuracies than pathway-based models, with
the best models reaching more than 90% accuracy on both datasets; however, these mod-
els only contain information on the relevance of single genes for the prediction and do not
enable an interpretation of the data on the level of cellular pathways and processes. Al-
though the simple decision rules generated by the TSPP algorithm do not reach the highest
accuracies obtained by the support vector machine on single genes, their high interpretabil-
ity and significant predictive information content allow the user to quickly identify cases,
in which the relative gene expression in pathway pairs is differentially regulated across
different biological conditions.
To investigate the utility of top-scored pathway pairs (TSPPs) in more detail, we have
mapped the genes in these pathways onto their corresponding proteins in a large-scale
protein-protein interaction network, consisting of 38857 interactions between 9392 pro-
teins assembled from direct binary interactions in a previous study [GBKV10]. Figure 2
a) shows the largest connected component of an example mapping for the TSPP with the
highest score on the Prostate cancer dataset, “hsa05215 Prostate cancer” vs. “hsa04910
Insulin signaling pathway” (see also Figure 1), revealing a strong network of interac-
tions between these pathways, which also share a significantly large set of overlapping
genes/proteins (q-value = 5.1E-17, when testing the hsa04910 pathway against all other
KEGG pathways using the one-sided Fisher exact test and adjusting for multiple testing
with the Benjamini-Hochberg method [BH95]). However, the TSPP-method also points
the user to differentially regulated pathway pairs which would not be detected as signif-
Table 4: Top-ranked pathway pairs (Prostate cancer data)
Rank Pathway 1 Pathway 2 Direction Score
1 hsa05215 Prostate hsa04910 Insulin down 0.81
cancer signaling pathway
2 hsa00240 Pyrimidine metabolism hsa00561 Glycerolipid metabolism up 0.80
3 hsa04540 Gap junction hsa05210 Colorectal cancer up 0.78
4 hsa04115 p53 signaling pathway hsa00230 Purine metabolism down 0.75
5 hsa04510 Focal adhesion hsa00071 Fatty acid metabolism down 0.75
6 hsa04514 Cell adhesion hsa04610 Complement and up 0.72
molecules (CAMs) coagulation cascades
7 hsa03050 Proteasome hsa01430 Cell Communication up 0.69
8 hsa04920 Adipocytokine hsa04730 Long-term up 0.69
signaling pathway depression
9 hsa04810 Regulation of hsa04530 Tight down 0.65
actin cytoskeleton junction
10 hsa04512 ECM-receptor interaction hsa04110 Cell cycle down 0.63
The 10 top-ranked pathways for the prostate cancer dataset based on the TSPP-score (Direction “down” means
that in the healthy control samples, pathway 1 is down-regulated in relation to pathway 2, whereas in the prostate
cancer samples, pathway 1 is up-regulated in relation to pathway 2, and respectively, “up” means the pathways
have opposite relations in the two sample classes).
icantly associated based on an overlap-based significance test, e.g. Figure 2 b) shows
the largest connected component for the TSPP “hsa04115 p53 signaling pathway” vs.
“hsa00230 Purine metabolism”, with only two overlapping proteins, but a multitude of
direct binary protein-protein interactions between the two pathways. Further experimen-
tal evidence for an association between these pathways is provided by a study showing
that the inhibition of de novo purine synthesis by the drug “AG2034”, which also inhibits
prostate cancer cell growth, increases the expression levels of p53 [OKM09]. Thus, al-
though the up- and down-regulation of top-scoring pathway pairs does not necessarily
result from a regulatory relationship between the pathways, the analysis of the TSPPs can
help to point the user to associations between pathways, which would remain unnoticed
by other methods, such as an overlap-based Fisher test.
.
3.1 Data sets
3.1.1 Diffuse large B-cell lymphoma (DLBCL)
The DLBCL data set [S+02a] contains expression values for 7,129 genes and 77 microar-
ray samples, 58 of which were obtained from patients suffering from diffuse large B-
cell lymphoma (D), while the remaining samples derive from a related B-cell lymphoma,
called follicular lymphoma (F). The experiments in this microarray study had been carried
out on an Affymetrix HU6800 oligonucleotide platform [Aff01].
To pre-process the raw data, we applied the “Variance stabilizing normalization” [HvHS+02]
Table 5: Top-ranked pathway pairs (B-Cell lymphoma data)
Rank Pathway 1 Pathway 2 Direction Score
1 hsa00020 Citrate hsa04310 Wnt signaling down 0.88
cycle (TCA cycle) pathway
2 hsa00052 Galactose hsa04664 Fc epsilon RI down 0.87
metabolism signaling pathway
3 hsa04670 Leukocyte hsa03050 Proteasome up 0.87
transendothelial migration
4 hsa04514 Cell adhesion hsa00030 Pentose up 0.86
molecules (CAMs) phosphate pathway
5 hsa04730 Long-term depression hsa00240 Pyrimidine metabolism up 0.85
6 hsa00562 Inositol hsa00051 Fructose an up 0.84
phosphate metabolism mannose metabolism
7 hsa00220 Urea cycle and hsa00980 Metabolism of xenobiotics down 0.84
metabolism of amino groups by cytochrome P450
8 hsa04540 Gap junction hsa00330 Arginine and up 0.84
proline metabolism
9 hsa00252 Alanine and hsa04630 Jak-STAT down 0.84
aspartate metabolism signaling pathway
10 hsa00970 Aminoacyl-tRNA hsa04912 GnRH down 0.81
biosynthesis signaling pathway
The 10 top-ranked pathways for the B-Cell lymphoma dataset based on the TSPP-score (Direction “down” means
that in the DLBCL samples, pathway 1 is down-regulated in relation to pathway 2, whereas in the follicular B-
cell lymphoma samples, pathway 1 is up-regulated in relation to pathway 2, and respectively, “up” means the
pathways have opposite relations in the two sample classes).
Figure 2: Analysing TSPPs in a protein-protein interaction network: a) Largest connected compo-
nent for KEGG pathways: “Prostate cancer” and “Insulin signaling” (blue: Prostate cancer, red:
Insulin signaling, green: members in both pathways); b) Largest connected component for KEGG
pathways “P53 signaling” and “Purine metabolism” (blue: P53 signaling, red: Purine metabolism,
green: members in both pathways)
to filter out intensity-dependent variance (this was done using the vsn-library and the
expresso-package in the R statistical learning environment [Tea10]). Moreover, we ap-
plied thresholding based on the suggestions in the supplementary material of the original
publication [S+02a] and a “fold change”-filter to remove all genes with less than a 3-fold
change between the maximum and minimum expression value.
3.1.2 Prostate cancer
The prostate cancer data set [S+02b] consists of expression measurements for 12,600 ge-
netic probes across 50 healthy control tissues (C) and 52 prostate cancer tissues (C). All
experiments have been carried out on Affymetrix Hum95Av2 arrays [Aff01]. Due to the
large number of samples and memory limitations of the expresso-package (used to normal-
ize the other two data sets), we applied the fast GeneChip RMA (GCRMA) normalization
algorithm [WI05]. Moreover, we employed thresholding based on the suggestions in the
original publication of the dataset [S+02b] and a fold change filter to remove all probes
with less than a 2-fold change between the maximum and minimum expression value.
Table 6: Data sets used in this paper
Data set Platform No. of No. of samples references
genes class 1; class 2
B-cell lymphoma Affymetrix 7,129 58 (D) ; 19 (F) [S+02a]
Prostate cancer Affymetrix 12,600 52 (T) ; 50 (C) [S+02b]
4 Conclusion
We present a new method for extracting pathway-based decision rules from combined
gene expression data and gene sets representing cellular pathways and processes. When
applying prediction models derived from these decision rules for sample classification on
two public microarray cancer datasets, we obtain compact and easily interpretable models
with significant predictive information content. The generated decision rules are robust
against monotonic transformations of the data, and the algorithm is easy to implement
and has a comparatively short run-time due to the reduction of the data dimensionality
when considering summarized pathway expression values instead of gene expression val-
ues. Moreover, these models also enable a different interpretation of microarray data by
analysing the data at the level of pathways. Specifically, the top-scoring pathway pairs can
point the user to regulatory relationships or other functional associations between the cor-
responding pathways. In summary, the TSPP algorithm provides both a novel method to
generate compact and accurate classification models and a new exploratory tool to analyse
microarray data at the level of pairwise pathway-relations.
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